MicroRNA 3591 (MIR3591)

MicroRNA 3591 (MIR3591) is a short non-coding RNA classified as a microRNA involved in post-transcriptional regulation of gene expression in multicellular organisms by targeting mRNAs for translational inhibition or destabilization. It is transcribed as a primary transcript processed by Drosha and Dicer enzymes to yield the mature miRNA, which then associates with the RNA-induced silencing complex (RISC) to mediate its regulatory effects[2]. Key notes: - MIR3591 is not considered a druggable or therapeutic target such as a receptor, enzyme, transporter, or transcription factor; rather, it is a non-coding RNA product with regulatory functions[2]. - There is some ambiguity and potential error: - MIR3591 is sometimes listed with the alias "hsa-mir-122b," but "hsa-mir-122b" is not a widely recognized or standard annotation in miRBase or the primary miRNA literature, raising concerns about synonym confusion or annotation errors. - No reputable data currently link MIR3591 or its aliases to disease, function, or therapeutic intervention. - No drugs or patient biomarkers are established, and no clear safety or biomarker profiles exist. - The available evidence is limited to basic molecular annotation, with no functional or disease associations reported in primary literature or databases[2]. Summary: MicroRNA 3591 (MIR3591) is a predicted human microRNA with limited characterization, no known function, disease role, or therapeutic targeting status, and possible annotation/aliasing confusion. It is best described as a regulatory non-coding RNA, with no current evidence supporting its use as a biomarker, therapeutic target, or disease-associated molecule in humans[2].

Other names

hsa-mir-3591hsa-mir-122bMIR3591